Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.39% 645.5 Delayed Quote.12.58%
ASTRAZENECA 0.92% 5478 Delayed Quote.5.99%
ROCHE HOLDING LTD. -0.64% 217.6 Delayed Quote.-9.17%
ROCHE HOLDING LTD. -0.63% 187.58 Delayed Quote.-10.49%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
05/25ASTRAZENECA : Study Data from AstraZeneca Provide New Insights into Breast Cance..
AQ
05/25ASTRAZENECA : Investigators at AstraZeneca Describe Findings in Catheterization ..
AQ
05/25ASTRAZENECA : Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Sid..
AQ
05/25INVESTIGATORS AT ASTRAZENECA ZERO IN : Is it the Dawn of a New Beginning?)
AQ
05/25ASTRAZENECA : IMFINZI® (Durvalumab) Significantly Improves Overall Survival in t..
BU
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/25ASTRAZENECA : Imfinzi significantly improves overall survival in the Phase III P..
PU
05/25AZ'S IMFINZI : significant OS in Stage III nsclc
AQ
05/25Innovation at the heart of development
AQ
05/24ASTRAZENECA : announces opening of new South San Francisco Site
AQ
More news
News from SeekingAlpha
05/25WALL STREET BREAKFAST, MAY 25TH : EU Data Privacy Rules Take Effect; U.S. And Ch.. 
05/25AstraZeneca's Imfinzi successful in late-state lung cancer study 
05/25WALL STREET BREAKFAST : New Privacy Bar With GDPR 
05/25Healthcare roundup 
05/24Merck Appears Unstoppable In Treating Front-Line Lung Cancer 
Financials ($)
Sales 2018 22 463 M
EBIT 2018 5 422 M
Net income 2018 1 896 M
Debt 2018 14 637 M
Yield 2018 3,78%
P/E ratio 2018 38,87
P/E ratio 2019 30,73
EV / Sales 2018 4,74x
EV / Sales 2019 4,46x
Capitalization 91 758 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,3 $
Spread / Average Target 2,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.99%91 758
JOHNSON & JOHNSON-11.45%327 893
PFIZER-1.16%209 941
NOVARTIS-6.94%193 872
ROCHE HOLDING LTD.-9.17%190 404
MERCK AND COMPANY5.08%159 078